Cancer Targeted Technology Highlights Prostate Cancer PET Imaging and Radiotherapeutic Advances

first_img Videos | Artificial Intelligence | July 22, 2019 VIDEO: Use of Machine Learning to Automate Radiotherapy Treatment Planning Leigh Conroy, Ph.D., physics resident, Universi read more News | Prostate Cancer | April 24, 2017 Cancer Targeted Technology Highlights Prostate Cancer PET Imaging and Radiotherapeutic Advances Company will share results of PSMA-targeted imaging and radiotherapeutic agents at numerous conferences from April-June Related Content Princess Margaret Cancer Center uses machine learning to create automated treatment plansVideo Player is loading.Play VideoPlayMuteCurrent Time 0:00/Duration 3:22Loaded: 4.83%Stream Type LIVESeek to live, currently playing liveLIVERemaining Time -3:22 Playback Rate1xChaptersChaptersDescriptionsdescriptions off, selectedCaptionscaptions settings, opens captions settings dialogcaptions off, selectedAudio Trackdefault, selectedFullscreenThis is a modal window.Beginning of dialog window. Escape will cancel and close the window.TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaqueFont Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall CapsReset restore all settings to the default valuesDoneClose Modal DialogEnd of dialog window.Close Modal DialogThis is a modal window. This modal can be closed by pressing the Escape key or activating the close button. News | Proton Therapy | July 17, 2019 Shorter Courses of Proton Therapy Equally Effective in Treating Prostate Cancer July 17, 2019 — Treating prostate cancer read more Technology | Interventional Radiology | August 16, 2019 Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to… read more News | Artificial Intelligence | July 26, 2019 Progenics Pharmaceuticals Collaborating With Veterans Affairs on AI Cancer Imaging Research Program Oncology company Progenics Pharmaceuticals Inc. announced their collaboration with the Veterans Affairs Greater Los… read more News | Radiopharmaceuticals and Tracers | August 02, 2019 ASRT Supports Radiopharmaceutical Reimbursement Bill The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure… read more center_img News | Interventional Radiology | July 31, 2019 International Multidisciplinary Group Publishes Recommendations for Personalized HCC Treatment With Y90 TheraSphere New consensus recommendations for personalized treatment for hepatocellular carcinoma (HCC) with BTG’s TheraSphere have… read more News | Radiopharmaceuticals and Tracers | July 16, 2019 NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-… read more April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal enzyme targets on cancer. CTT’s theranostic program is focused on the development of two drugs, CTT1057 and CTT1403, that respectively diagnose and treat prostate cancer based on targeting the biomarker prostate-specific membrane antigen (PSMA).PSMA is over-expressed on prostate cancer, and this expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s phosphoramidate-based agents bind irreversibly to PSMA, and unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells, leading to enhanced accumulation of the drugs within the tumor. Initial clinical data on CTT’s drugs in prostate cancer will be presented at five scientific and business meetings in April-June 2017.CTT’s diagnostic positron emission tomography (PET) imaging agent, CTT1057, is radiolabeled with fluorine-18, and commenced clinical trials in patients with metastatic prostate cancer in Nov. 2016. The study is currently enrolling patients.Upcoming presentations on the initial data from the CTT1057 clinical trial include:American Society of Clinical Oncologists meeting in Chicago, June 2-6, 2017“First-In-Human Phase 1 PET Study of CTT1057, a Novel 18F-Labeled Imaging Agent Targeting Prostate Specific Membrane Antigen (PSMA) in Prostate Cancer”Society of Nuclear Medicine and Medical Imaging meeting in Denver, June 10-14, 2017.“Comparison of a novel fluorine-18 labeled PSMA-targeting agent, CTT1057, to gallium-68 PSMA-11 in patients with prostate cancer”; and“First-in-Human PET studies with CTT1057, a novel fluorine-18 labeled agent, targeting PSMA in prostate cancer”CTT’s radiotherapeutic drug, CTT1403, is radiolabeled with lutetium-177, and is in late-stage preclinical development, with clinical trials planned for 2018. CTT1403 is uniquely designed to maximize tumor uptake, while minimizing side effects to normal tissues.Presentations on CTT1403 radiotherapeutic agent include:American Chemical Society meeting in San Francisco, April 2-6, 2017“Improving the In Vitro and In Vivo Performance of a 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitor with an Albumin-Binding Motif”; andSNMMI 2017“Comparison of traditional and albumin-binding Lu-177-labeled phosphoramidate-based PSMA inhibitors for targeted radionuclide therapy of prostate cancer”For more information: www.cancertargetedtechnology.com FacebookTwitterLinkedInPrint分享 News | Brachytherapy Systems | August 14, 2019 Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica read more News | Radiopharmaceuticals and Tracers | July 26, 2019 NorthStar Medical Radioisotopes Awarded $30 Million by U.S. Department of Energy NorthStar Medical Radioisotopes LLC has been awarded $15 million in a cooperative agreement with the U.S. Department of… read more News | PET-CT | August 15, 2019 United Imaging Announces First U.S. Clinical Installation of uExplorer Total-body PET/CT United Imaging announced that its uExplorer total-body positron emission tomography/computed tomography (PET/CT) system… read more last_img read more